Aggrenox: Dual-Antiplatelet Protection for Secondary Stroke Prevention
| Product dosage: 225mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 20 | $2.51 | $50.20 (0%) | 🛒 Add to cart |
| 30 | $1.91 | $75.30 $57.23 (24%) | 🛒 Add to cart |
| 60 | $1.62 | $150.61 $97.39 (35%) | 🛒 Add to cart |
| 90 | $1.41 | $225.91 $126.51 (44%) | 🛒 Add to cart |
| 120 | $1.26 | $301.22 $151.61 (50%) | 🛒 Add to cart |
| 180 | $1.09 | $451.82 $195.79 (57%) | 🛒 Add to cart |
| 270 | $0.90 | $677.74 $243.99 (64%) | 🛒 Add to cart |
| 360 | $0.80
Best per pill | $903.65 $289.17 (68%) | 🛒 Add to cart |
Synonyms | |||
Aggrenox is a prescription medication specifically formulated to reduce the risk of recurrent stroke in patients who have experienced a previous ischemic stroke or transient ischemic attack (TIA). It combines two active antiplatelet agents—aspirin and dipyridamole—in an extended-release formulation designed to work synergistically. This combination targets distinct pathways of platelet aggregation, offering a comprehensive approach to thromboembolic risk reduction. By inhibiting clot formation through complementary mechanisms, Aggrenox provides a robust therapeutic option backed by clinical evidence demonstrating significant efficacy in long-term vascular protection.
Features
- Contains a fixed-dose combination of 25 mg aspirin and 200 mg extended-release dipyridamole per capsule
- Utilizes a proprietary extended-release formulation for consistent dipyridamole delivery
- Dual mechanism of action targeting both cyclooxygenase-1 and phosphodiesterase inhibition
- Convenient twice-daily dosing regimen
- FDA-approved for secondary stroke prevention
- Available in capsule form with specific pharmacokinetic properties
Benefits
- Significantly reduces the relative risk of recurrent stroke compared to aspirin monotherapy
- Provides complementary antiplatelet activity through two distinct pharmacological pathways
- Offers convenient dosing that supports long-term adherence to therapy
- Demonstrates proven efficacy in large-scale clinical trials with long-term follow-up
- May provide more consistent antiplatelet effects than single-agent therapies
- Supported by clinical guidelines for secondary stroke prevention in appropriate patients
Common use
Aggrenox is primarily indicated for the secondary prevention of ischemic stroke in patients who have experienced a previous cerebrovascular event. It is specifically approved for reducing the risk of recurrent stroke in patients who have had ischemic stroke or transient ischemic attack (TIA). The medication is typically prescribed as part of a comprehensive vascular risk reduction strategy that may include blood pressure management, cholesterol control, and lifestyle modifications. Clinical trials have demonstrated its superiority over aspirin alone in preventing recurrent stroke events, making it a valuable option in neurology and vascular medicine practice.
Dosage and direction
The recommended dosage of Aggrenox is one capsule taken orally twice daily, approximately 12 hours apart. The capsules should be swallowed whole with a full glass of water and should not be crushed, chewed, or opened. Administration with food may help minimize gastrointestinal discomfort. Treatment is typically initiated as soon as patients are medically stable following an ischemic stroke or TIA, and continued indefinitely unless contraindications develop or significant adverse effects occur. Dose adjustments are not typically required for this fixed combination product, though special consideration may be necessary in certain patient populations.
Precautions
Patients should be carefully evaluated for bleeding risk before initiating Aggrenox therapy. Caution is advised in patients with history of gastrointestinal ulceration, bleeding disorders, or recent surgical procedures. Hepatic impairment may affect dipyridamole metabolism, requiring careful monitoring. Renal impairment does not significantly affect aspirin pharmacokinetics at this low dose, but caution is still warranted in severe renal dysfunction. Patients should be advised about the increased risk of bleeding and instructed to report any unusual bruising, bleeding, or signs of hemorrhagic events promptly. Regular monitoring of complete blood count may be appropriate during long-term therapy.
Contraindications
Aggrenox is contraindicated in patients with known hypersensitivity to aspirin, dipyridamole, or any component of the formulation. It should not be used in patients with asthma exacerbated by salicylates or NSAIDs. Additional contraindications include active pathological bleeding, severe hepatic impairment, and severe renal failure. The medication is contraindicated in children and teenagers with viral infections due to the risk of Reye’s syndrome associated with aspirin content. Concomitant use with other anticoagulants or antiplatelet agents generally represents a contraindication unless specifically indicated under careful medical supervision.
Possible side effects
The most common adverse reactions include headache (approximately 15-20% of patients), dyspepsia (8-10%), abdominal pain (6-8%), and diarrhea (4-6%). These effects often diminish with continued therapy. More serious potential side effects include gastrointestinal bleeding (1-2%), hemorrhagic stroke (<1%), and severe allergic reactions. Patients may experience dizziness, nausea, or vomiting, particularly during initial treatment. The extended-release formulation of dipyridamole may cause vasodilation-related effects including flushing or hypotension in some individuals. Any signs of bleeding complications require immediate medical evaluation.
Drug interaction
Aggrenox has significant interaction potential due to its dual antiplatelet activity. Concomitant use with anticoagulants (warfarin, dabigatran, rivaroxaban, apixaban) or other antiplatelet agents (clopidogrel, prasugrel, ticagrelor) significantly increases bleeding risk. NSAIDs may potentiate gastrointestinal toxicity and bleeding risk. ACE inhibitors’ antihypertensive effects may be reduced by aspirin component. Dipyridamole may potentiate effects of adenosine and other cardiac medications. Cholinesterase inhibitors may have reduced efficacy when combined with aspirin. Proton pump inhibitors or H2 antagonists may be considered for gastroprotection in high-risk patients.
Missed dose
If a dose is missed, patients should take it as soon as remembered unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not double the dose to make up for a missed administration. Consistency in dosing is important for maintaining antiplatelet effects, but occasional missed doses are unlikely to significantly impact overall efficacy. Patients should be educated about the importance of adherence and encouraged to develop routines that support regular dosing.
Overdose
Aspirin overdose may cause tinnitus, hyperventilation, metabolic acidosis, and respiratory alkalosis. Dipyridamole overdose may result in pronounced vasodilation with hypotension, flushing, dizziness, and tachycardia. Severe overdose can lead to hemorrhagic complications, seizures, or cardiovascular collapse. Management requires immediate medical attention with supportive care including gastric lavage if presented early, activated charcoal administration, and careful monitoring of coagulation parameters. Specific treatments may include alkaline diuresis for salicylate toxicity and vasopressor support for dipyridamole-induced hypotension. Hemodialysis may be considered in severe cases.
Storage
Aggrenox capsules should be stored at controlled room temperature (20-25°C or 68-77°F) with excursions permitted between 15-30°C (59-86°F). The medication should be kept in its original container with the lid tightly closed to protect from moisture. Capsules should not be stored in bathroom cabinets or other areas with high humidity. Keep out of reach of children and pets. Do not use beyond the expiration date printed on the packaging. Proper storage ensures maintenance of the extended-release properties and medication stability.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Aggrenox is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Individual patient needs may vary, and treatment decisions should be based on comprehensive medical evaluation. Patients should consult their healthcare provider for personalized medical advice and report any adverse effects or concerns promptly. The prescribing information provided here may not include all possible uses, directions, precautions, or interactions.
Reviews
Clinical studies demonstrate that Aggrenox reduces the relative risk of recurrent stroke by approximately 22% compared to aspirin alone based on the ESPRIT trial data. Many neurologists report positive experiences with the medication in appropriate patient populations, noting its efficacy in secondary prevention. Some patients report initial headache that typically resolves within several weeks of continued therapy. Adherence rates are generally favorable due to the twice-daily dosing schedule. The combination therapy is often viewed favorably compared to monotherapy options in high-risk patients, though individual response and tolerance should guide treatment decisions.